146 related articles for article (PubMed ID: 24422692)
1. Darbepoetin alfa for anemia in chronic kidney disease.
Agarwal AK
Expert Rev Clin Pharmacol; 2008 May; 1(3):369-79. PubMed ID: 24422692
[TBL] [Abstract][Full Text] [Related]
2. Darbepoetin alfa: a novel erythropoiesis-stimulating protein.
Cases A
Drugs Today (Barc); 2003 Jul; 39(7):477-95. PubMed ID: 12973399
[TBL] [Abstract][Full Text] [Related]
3. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
4. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
[TBL] [Abstract][Full Text] [Related]
5. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC;
Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
[TBL] [Abstract][Full Text] [Related]
6. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
Wish JB; Coyne DW
Mayo Clin Proc; 2007 Nov; 82(11):1371-80. PubMed ID: 17976358
[TBL] [Abstract][Full Text] [Related]
7. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
Mahajan S; Boulton H; Gokal R
J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
[TBL] [Abstract][Full Text] [Related]
8. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
[TBL] [Abstract][Full Text] [Related]
9. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
Nurko S; Spirko R; Law A; Dennis VW
Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
[TBL] [Abstract][Full Text] [Related]
10. Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management.
Vansteenkiste JF
Cancer Treat Rev; 2006; 32 Suppl 2():S11-5. PubMed ID: 16725268
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
[TBL] [Abstract][Full Text] [Related]
12. Initiation of darbepoetin for management of anemia in non-dialysis-dependent patients with chronic kidney disease.
Al Raisi F; Al Salmi I; Kamble P; Al Shehri M; Shaheen FA
Saudi J Kidney Dis Transpl; 2016; 27(6):1182-1187. PubMed ID: 27900963
[TBL] [Abstract][Full Text] [Related]
13. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
14. Darbepoetin alfa: a novel erythropoiesis-stimulating protein.
Joy MS
Ann Pharmacother; 2002; 36(7-8):1183-92. PubMed ID: 12086553
[TBL] [Abstract][Full Text] [Related]
15. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients.
Jadoul M; Vanrenterghem Y; Foret M; Walker R; Gray SJ
Nephrol Dial Transplant; 2004 Apr; 19(4):898-903. PubMed ID: 15031347
[TBL] [Abstract][Full Text] [Related]
16. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
Hoggard J; Crouch T; McMurray S; Levine M; Prathikanti R; Scarlata D; Audhya P
Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
[TBL] [Abstract][Full Text] [Related]
17. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
18. Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data.
Carrera F; Disney A; Molina M
Nephrol Dial Transplant; 2007 Jun; 22 Suppl 4():iv19-iv30. PubMed ID: 17526546
[TBL] [Abstract][Full Text] [Related]
19. Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease.
Hertel JE; Locay HR; Scarlata DS; Prathikanti R; Audhya PK
Mayo Clin Proc; 2006 Sep; 81(9):1188-94. PubMed ID: 16970215
[TBL] [Abstract][Full Text] [Related]
20. An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis.
Padhi D; Ni L; Cooke B; Marino R; Jang G
Clin Pharmacokinet; 2006; 45(5):503-10. PubMed ID: 16640455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]